Sustained Efficacy
8. Weinstock-Guttman B et al. Poster 388 presented at AAN 2017
8. Weinstock-Guttman B et al. Poster 388 presented at AAN 2017
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
MONALEESA-2 OS BY DOSE REDUCTION poster discussion | Hart LL In this exploratory analysis of ML-2, 1L RIB + LET maintained OS benefit in postmenopausal pts with HR+, HER2...
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Two phase III, randomised, double-blind, placebo-controlled studies RAISE (TRA102537) and TRA100773B and two open-label studies REPEAT (TRA108057) and EXTEND (TRA105325)...
Over the past 10 years, the treatment landscape of SpA went through a substantial change, with an expansion of new therapies and new modes of action. Guidelines and recommendations have been developed to...